Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VSTM vs SANA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SANA Captures Overall Composite Edge (44.3 HOLD vs 56.9 HOLD), While VSTM Leads 4–1 on Growth & Valuation Pillars

SANA Overall Winner 6-Pillar Tally: VSTM 4 – 1 SANA (1 Tie) Matrix Metrics: VSTM 5 – 3 SANA

As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (44.3/100 HOLD vs. 56.9/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality), while VSTM wins 4–1 across the 6-pillar growth and valuation breakdown. VSTM trades at $7.70 (N/M Forward P/E, -193.7% operating margin) versus SANA at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (56.9/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY).
  • Technical & Structure Timing Caution: VSTM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VSTM vs SANA
VSTM NASDAQ
Verastem, Inc.
Pharmaceutical Preparations
$7.70
-5.87% 1D
Market Cap $1.0B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.11β · 71% Vol
Unified Composite Score
56.9 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $9.30 · SMA50: $8.48
SANA NASDAQ Head-to-Head Winner
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (VSTM 4 – 1 SANA)

Columns: Metric · VSTM · SANA
1. Valuation Multiples VSTM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.8x N/M
2. Growth & Scale VSTM
Revenue Growth (YoY) +113.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $100M N/A
Market Cap $1.0B $605.3M
3. Profitability & Quality SANA
Gross Margin 87.2% N/A
Operating Margin -193.7% 0.0%
Net Profit Margin -178.4% 0.0%
Return on Equity (ROE) -471.2% -79.5%
4. Balance Sheet & Cash Flow VSTM
Cash Generation (TTM) -$168M -$145M
Cash Flow Margin N/A N/A
Net Cash / Leverage $44M Net Cash $13M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VSTM
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 88.4% (8th %ile) 105.5% (4th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.61x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VSTM (5) vs SANA (3)
Institutional Metric VSTM SANA Criterion Row Edge
Market Capitalization
Scale
$1.0B $605.3M Larger Scale VSTM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+113.6% +0.0% Higher Growth VSTM
Operating Margin (TTM)
Profitability
-193.7% 0.0% Higher Margin SANA
Net Profit Margin
Profitability
-178.4% 0.0% Higher Margin SANA
Return on Equity (ROE)
Capital Efficiency
-471.2% -79.5% Higher ROE SANA
52-Week Range Position
Momentum
58% ($3–$11) 1% ($2–$5) Stronger Trend VSTM
Beta / 30D Volatility
Risk Regime
1.11β · 71% Vol 1.82β · 78% Vol Lower Realized Risk VSTM
Unified Institutional Score
Composite Signal
56.9 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite VSTM
Trailing 12M Revenue (USD)
Operating Scale
$100M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$168M ($44M Net Cash) -$145M ($13M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VSTM +6.2 pp
VSTM: -10.98% · SANA: -17.18%
3M Horizon VSTM +51.84 pp
VSTM: +3.63% · SANA: -48.21%
6M Horizon VSTM +118.91 pp
VSTM: +80.75% · SANA: -38.16%
1Y Horizon VSTM +43.57 pp
VSTM: -5.06% · SANA: -48.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VSTM vs SANA. Trailing 12-month operating profitability (VSTM -193.7% vs SANA 0.0%) and valuation multiples (VSTM N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VSTM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$100M
Gross Margin87.2%
Op. Margin-193.7%
ROE / Fwd P/E-471.2% · N/M
SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VSTM CONSOLIDATION
50d in phase · OBV NEUTRAL
Current IV 88.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VSTM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and -193.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VSTM vs SANA Key Questions & Quantitative Answers

As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (44.3/100 HOLD vs. 56.9/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality), while VSTM wins 4–1 across the 6-pillar growth and valuation breakdown. VSTM trades at $7.70 (N/M Forward P/E, -193.7% operating margin) versus SANA at $1.88 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (56.9/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY). Technical & Structure Timing Caution: VSTM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VSTM leads the Growth & Scale pillar: VSTM posts +113.6% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (87.2% gross margin, -193.7% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VSTM generates $100M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, VSTM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.

VSTM screens cheaper on headline valuation multiples. VSTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (unreported FCF margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VSTM (-471.2% ROE) versus SANA (-79.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VSTM carries 88.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 71% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.